Urology News Articles▼ Show details
Search today's latest Urology news articles updated daily summarizing the most recent top clinical literature from over 2,000 peer-reviewed journals, including Journal of Urology, European Urology, The Prostate, and more. Read coverage of the kidney, bladder, penis/urethra and prostate. View article summaries by subspecialty and disease state, including pediatric urology, urologic oncology, kidney stone disease, infections and STDs, urologic imaging, ureteral disorders, voiding and incontinence, infertility, laparoscopy and other surgical techniques in Urology.
Chromogranin A staining as a biomarker for prostate adenocarcinoma
As reported in The Prostate, chromogranin A (CgA) staining, an indicator of neuroendocrine differentiation, is associated with decreased biochemical control, clinical failure, increased distant metastases, and decreased cause-specific survival in patients with prostate adenocarcinoma and a GS ≥ 7 (n=285). The median follow-up was 6.5 y. CgA staining was present in 31% of specimens. The 10-y distant metastases rate in specimens with <1% and >1% CgA staining was 8% and 48%, respectively. The 10-y cause-specific survival in specimens with <1% and >1% CgA staining was 95% vs. 76%, respectively.
PCA3 useful for early diagnosis of prostate cancer
Based on a meta-analysis reported in the Chinese Medical Journal, prostate cancer antigen 3 (PCA3) can be used for the early diagnosis of prostate cancer and to avoid unnecessary biopsies, with a sensitivity of 0.82, a specificity of 0.962, a positive likelihood ratio of 2.39, a negative likelihood ratio of 0.51, and a diagnostic odds ratio of 4.89.
3-month PSA is a predictor of BCR-free survival after radical prostatectomy
As reported in the International Journal of Clinical Oncology, the 5-year biochemical recurrence (BCR)-free survival rate is significantly higher in patients with a 3-month PSA level < 0.010 ng/ml compared to patients with a 3-month PSA level between 0.010 and 100 ng/ml (92.6% vs. 57.4%). Amongst 174 men who underwent radical prostatectomy for clinically localized prostate cancer, 18.4% had a BCR and the median time to BCR was 16 months.